Immunocore Holdings plc

IMCR

$1.60B

Small Cap

NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaOXFORDSHIRE

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 15, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

3 upcoming, 0 past

Phase 2Next

Brenetafusp Phase 2 Results Expected

February 2026~Brenetafusp727

Primary completion for Brenetafusp trial (NCT04262466) in Select Advanced Solid Tumors

Source

🎯PDUFA

FDA PDUFA Date tebentafusp-tebn (priority)

6/18/2026

For unresectable or metastatic uveal melanoma. BLA filing. Extracted from SEC filing: 8-K

Source

Phase 2

IMC-R117C Phase 2 Results Expected

Nov 30, 2026IMC-R117C600

Primary completion for IMC-R117C trial (NCT06840119) in Cancer

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Brenetafusp

Phase 3

Select Advanced Solid Tumors

Tebentafusp

Phase 3

Advanced Melanoma

IMC-R117C

Phase 2

Cancer

Dacarbazine

Phase 2

Uveal Melanoma

IMCgp100

Phase 2

Uveal Melanoma

Drug Name	Phase	Indication	Designations
Brenetafusp	Phase 3	Select Advanced Solid Tumors	-
Tebentafusp	Phase 3	Advanced Melanoma	-
IMC-R117C	Phase 2	Cancer	-
Dacarbazine	Phase 2	Uveal Melanoma	-
IMCgp100	Phase 2	Uveal Melanoma	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

IMCR News